Invited International Experts

Associate Professor Martha Grogan

Associate Professor of Medicine, Cardiologist, Mayo Clinic College of Medicine

Associate Professor Grogan is a native of Cincinnati, Ohio, and a graduate of the University of Cincinnati (1976) and Northwestern University Medical School (1984). She is a cardiologist with more than 25 years of experience in clinical research of cardiovascular disease and the founder and director of Cardiac Amyloid Clinic at Mayo Clinic, Rochester. Her current area of focus is cardiac amyloidosis, with previous projects in adult congenital heart disease and heart failure. Areas of clinical research include studies analyzing diagnostic imaging, treatment, and outcomes for patients with cardiac amyloidosis.

Associate Professor Grogan has authored numerous scientific studies with other leading amyloid experts in addition to publishing textbooks chapters covering a range of cardiac disorders, imaging techniques, and treatments. She has developed a successful cardiac amyloid clinical trial research program and is a national and international leader in accrual. Her work at the Mayo Clinic Rochester is not only dedicated to the study of cardiac amyloidosis and education of health care providers but is also focused on the education of the general public in heart health.

Associate Professor Grogan is respected by the international community not only for her expertise and academic achievements but also for her generosity in sharing her knowledge and dedication to the education and support of physicians and patients alike worldwide.

Dr Murielle Roussel

Senior Consultant, Clinical Hematology and Cellular Therapy, CHU Dupuytren, Limoges, France (The French National Center for AL Amyloidosis and monoclonal deposition disease)

Dr Roussel received her medical degree at the University of Paris-Lariboisière, St Louis, France in 2002. She completed haematology specialist training in Paris and was granted a Master of Science in blood cell biology at the University of Paris VII-Denis Diderot in 2001. She has worked alongside leading plasma cell dyscrasia experts including Professor Michel Attal at Institut Universitaire du Cancer Toulouse Oncopole (2005-2021) and is currently working with Professor Arnaud Jaccard at the Centre Hospitalier Universitaire de Limoges.

Dr Roussel is a Senior Haematologist at the French National Centre for AL amyloidosis and Clinical Haematology Service in CHU Dupytron, Limoges. She has also been a PhD student since 2021 at the Controle de la Response Immune B et Lyphoproliferartions (CRIBL) Lab directed by Professor Christophe SIRAC.

Dr Roussel has published in books and journals in the fields of multiple myeloma and AL. She is highly active in clinical trials for Multiple Myeloma and AL and is an investigator with both the Intergroupe Fracnophone de Myelome (IFM) and French AL Amyloidosis network. She has been the co-ordinating principle investigator for international clinical research projects in AL.

Isabelle Lousada

President and CEO of the Amyloidosis Research Consortium (ARC)

Isabelle Lousada is President and CEO of the Amyloidosis Research Consortium (ARC). She previously served as Chairman of the Board for the Amyloidosis Foundation (2010-2016) and board and committee members of the International Myeloma Foundation and Myeloma UK.

Ms. Lousada was also diagnosed with AL amyloidosis at a young age and was one of the first patients to successfully undergo a stem cell transplant. Ms. Lousada has gone on to become a pioneer in patient advocacy and research in the rare diseases field. She has been the driving force behind ARC, building successful collaborations and funded research programs across the sectors to advance the science and understanding of the amyloidosis diseases.

For the past 25 years, she has worked to bring patients, academia, regulators and industry together to develop partnerships, promote awareness, and address the critical unmet needs. She has been committed to empowering patients, increasing access, and improving care. Her work has led to tangible and positive outcomes for patients, families, and the wider medical community.